5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS
申请人:Idenix Pharmaceuticals LLC
公开号:EP2513113B1
公开(公告)日:2018-08-01
US8362068B2
申请人:——
公开号:US8362068B2
公开(公告)日:2013-01-29
US9187496B2
申请人:——
公开号:US9187496B2
公开(公告)日:2015-11-17
[EN] 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C À BASE DE 5,5-ARYLÈNE OU HÉTÉROARYLÈNE CONDENSÉ
申请人:IDENIX PHARMACEUTICALS INC
公开号:WO2011075615A1
公开(公告)日:2011-06-23
Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. Formula (I), (IA), (IB).
[EN] METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR<br/>[FR] PROCÉDÉS POUR TRAITER UNE INFECTION PAR VIRUS DE L'HÉPATITE C PHARMACORÉSISTANT PAR UN INHIBITEUR DE VIRUS DE L'HÉPATITE C CONSISTANT EN ARYLÈNES OU HÉTÉROARYLÈNES FUSIONNÉS EN 5,5
申请人:IDENIX PHARMACEUTICALS INC
公开号:WO2012135581A1
公开(公告)日:2012-10-04
Provided herein are methods for treating or preventing drug-resistant hepatitis C virus infection in a subject, which comprises administering to the subject a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, for example, of Formula I, IA, or IB.